Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations

Core Viewpoint - A lawsuit has been filed against Amylyx Pharmaceuticals for allegedly providing false or misleading statements to investors regarding its financial performance and prescription data for its drug RELYVRIO [1][2][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased shares between November 11, 2022, and November 8, 2023 [1]. - The lawsuit claims that Amylyx overstated the commercial prospects and prescription rates of RELYVRIO and attempted to conceal negative trends by blocking analysts from accessing prescription data [4]. Group 2: Financial Performance - On November 9, 2023, Amylyx Pharmaceuticals reported disappointing Q3 financial results, indicating a slowdown in new prescriptions due to increased discontinuations [3]. - Company management stated that 60% of patients remained on RELYVRIO therapy six months after initiation in the U.S. [3]. Group 3: Market Reaction - Following the announcement of the financial results, Amylyx Pharmaceuticals' shares fell over 31% on November 9, 2023, significantly impacting investors [4].